Interview: Mark Yang, Country Manager, Hospira Taiwan
In 2010, you began your last interview with us by mentioning two things: that because of the nature of this affiliate’s portfolio—with only 35% of revenues generated by pharma at…
Address: 18F, 333 DunHua S. Rd., Sec. 2, DaAn District, Taipei 10669, 10669 台北市敦化南路二段333號18樓,Taiwan
Tel: +886 3 3865117
Hospira is a global specialty pharmaceutical and medication delivery company dedicated to Advancing Wellness™ through the right people and the right products. As the world leader in specialty generic injectable pharmaceuticals, Hospira offers one of the broadest portfolios of generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management solutions.
The name ‘Hospira’ is derived from the words hospital, spirit, inspire and the Latin word spero, which means hope. It reflects the company’s primary market focus and expresses the hope and optimism that are critical in the healthcare industry.
Hospira focuses mainly on medical devices in the Taiwanese market, but is currently looking to expand its portfolio and increase its offering of generic drugs.
In 2010, you began your last interview with us by mentioning two things: that because of the nature of this affiliate’s portfolio—with only 35% of revenues generated by pharma at…
What is exciting about the Taiwanese market for Hospira today? Hospira is a US-based company, which used to be part of Abbott Laboratories. A major part of the portfolio for…
Ingo Brandenburg, managing director of Bayer Taiwan, brings over two decades of international pharmaceutical experience spanning Asia, Latin America, and Europe. With previous leadership roles, he has cultivated a deep…
Taiwan is, in many ways, a healthcare model for Asia. The island has had universal health coverage for over 30 years and Taiwan’s life expectancy today is almost 81 years,…
Vincent Tong, Managing Director of MSD Taiwan, brings two decades of pharmaceutical expertise to his second tenure leading the organisation in Taiwan. Having first served in Taiwan in 2008, Tong…
Professor Pan Chyr Yang is a clinician-scientist with an MD and PhD in pulmonary medicine, holding joint appointments at Academia Sinica and former university leadership roles in National Taiwan University. Recognised…
With its thriving innovation ecosystem and growing global visibility, Taiwan is fast emerging as one of Asia’s most dynamic biotechnology hubs. At the forefront of this transformation is Wallace Lin,…
Dr Chih-Kang Chiang, Director-General of the TFDA, shares how Taiwan is redefining regulation through science, transparency, and international collaboration. Combining his backgrounds in medicine, toxicology, and law, he leads efforts…
After more than two decades in Silicon Valley, Dr Jeng Her returned to Taiwan with a bold ambition: to help transform its emerging biotech sector into a globally recognised force…
Dr Wen-Liang Huang, General Manager of Ever Supreme Biotechnology, brings over 40 years of clinical cardiology experience to biopharmaceutical leadership. Recruited by the company’s founder, his medical background informs the…
Dr Chiu-Heng Chen (John), CEO of LaunXP, brings a unique perspective to oncology drug development shaped by his personal experience with cancer during his PhD in the UK. Holding advanced…
Taiwan’s healthcare system stands among the most advanced and accessible in Asia, yet, as the IRPMA’s CW Chen points out, sustainability is now the central concern. Drawing on a career…
Carl Wegner, President of AmCham Taiwan, reflects on his first months in the role, highlighting the chamber’s advocacy mission, the strength of its committees, growing US–Taiwan engagement, and major opportunities…
As a part of the World Health Organisation’s (WHO) COVID-19 Technology Access Pool (C-TAP), the Medicines Patent Pool has signed a worldwide license with Medigen Vaccine Biologics (MVC) for its…
See our Cookie Privacy Policy Here
